ERNA
Ernexa TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The constructive primary-source case is that management has linked pre-IND feedback, tech transfer, and a planned first-in-human path for ERNA-101, while the February 2026 financing reduced immediate cash pressure enough to pursue near-term preparatory work.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Clinical and manufacturing execution risk is still substantial because ERNA-101 remains preclinical and must complete manufacturing, IND-enabling work, IND submission, and trial initiation before the thesis can move beyond a monitoring setup.
Momentum
93
Value
42
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.14 · Bull $0.32 · Bear $0.05
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-01 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Why
Momentum93 · Δ7d -
Value42 · Δ7d +0.1
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
93
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
42
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 93.4 / Value 41.9 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$10.64M
Beta
6.47
Shares Out
7.85M
P/E (TTM) · Derived
-0.0
P/S (TTM)
9497.16
P/FCF (TTM) · Derived
-0.70
Rev YoY
-100.0%
EPS YoY
+99.8%
Gross Margin
+100.0%
Op Margin
-918700.0%
Net Debt
-$1.73M
Current Ratio
1.58
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology